B-Cell Lymphoblastic Lymphoma
Associated Genetic Biomarkers
NCI Definition: An uncommon type of lymphoma. It constitutes approximately 10% of cases of lymphoblastic lymphoma. Approximately 75% of cases reported in a literature review involved patients who were less than 18 years of age. The most commonly affected sites are the skin, bone, soft tissue, and lymph nodes. It has a high remission rate with a median survival of approximately 60 months. (WHO, 2001) 
There are 9 clinical trials for B-cell lymphoblastic lymphoma, of which 9 are open and 0 are completed or closed. Of the trials that contain B-cell lymphoblastic lymphoma as an inclusion criterion, 2 are early phase 1 (2 open), 2 are phase 1 (2 open), 4 are phase 2 (4 open), and 1 is phase 3 (1 open).
CD19, CD22, and MS4A1 are the most frequent gene inclusion criteria for B-cell lymphoblastic lymphoma clinical trials .
Vincristine, cyclophosphamide, and prednisone are the most common interventions in B-cell lymphoblastic lymphoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.